Although much evidence has been gathered demonstrating that immune effectors can play a
significant role in controlling tumor growth under natural conditions or in response to
therapeutic manipulation, it is clear that malignant cells do evade immune surveillance in
most cases. Considering that anticancer active specific immunotherapy seems to have
reached a plateau of results and that currently no vaccination regimen is indicated as a
standard anticancer therapy, the dissection of the molecular events underlying tumor …